Associated Papers
Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example.
Zheng S et al.
Molecular Biomedicine, 2024
Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
Liu B et al.
Cancer Medicine, 2022
35393784 (PubMed )
Supplement: CAM4-11-2767-s001.xlsx › Table_S2
PIK3CA Gene Mutations in HNSCC: Systematic Review and Correlations with HPV Status and Patient Survival.
Cochicho D et al.
Cancers, 2022
35267596 (PubMed )
Supplement: cancers-14-01286-s001.zip › Table_S3-HNSCC_PIK3CA_Mutational_profile.pdf
Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer.
Yi Z et al.
Npj Breast Cancer, 2020
33145402 (PubMed )
Supplement: 41523_2020_201_MOESM2_ESM.xlsx › Supplementary_Table_1
Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.
Al-Amri AM et al.
Cancer Biomarkers : Section a of Disease Markers, 2016
Germline and Somatic mutations in postmenopausal breast cancer patients.
Nagy TR et al.
Clinics (sao Paulo, Brazil), 0
Select a paper to view details